Prof. Solange Peters, MD, PhD, PD-MER [7505]
What is the trial-based evidence that targeted therapy using NGS-generated molecular markers, including EGFR, in NSCLC, represents a validated approach for improving clinical outcomes in patients with cancer? (French)
What is the trial-based evidence that targeted therapy using NGS-generated molecular markers in lung cancer represents a validated approach for improving clinical outcomes in patients with cancer? (French)
What are the implications of detecting an ALK rearrangement in patients with metastatic NSCLC and how would the detection of this genomic alteration influence your therapeutic strategy? What are the therapeutic implications as far as primary ...
If HER2 rearrangements are documented in NSCLC, why are such agents as trastuzimab and afatinib considered by the NCCN to have “targeted activity” against this tumor profile? (French)
If BRAF V600E mutations are documented in NSCLC, why are such agents as vemurafenib and dabrafenib considered by the NCCN to have “targeted activity” against this tumor profile? What other co-existing mutations, including MEK, detected ...
What are the therapeutic implications with respect to use of crizotinib in patients with translocation of ROS1 in NSCLC? What clinical study-based support—improvements in PFS and/or OS—suggests high activity of this agent in patients with ...
What are the validation trials that support crizotinib in patients with translocation of ROS1 in NSCLC? (French)
If MET amplification is documented in NSCLC, why is crizotinib considered by the NCCN to have “targeted activity” against this tumor profile? What clinical study-based support—improvements in PFS and/or OS—suggests high activity of this ...
Is there any role for the use of NGS in determining immunotherapeutic approaches that deploy immunotherapy? (French)
What is the foundational role of NGS, hybrid capture-based technology for improving clinical outcomes in patients with NSCLC and other solid tumors? (French)